Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Infect ; 88(1): 2-14, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38007049

ABSTRACT

BACKGROUND: The sudden outbreak of severe acute hepatitis of unknown aetiology (SAHUA) in the first half of 2022 affected more than 1010 children in 35 countries worldwide. Dire clinical outcomes, such as acute liver failure necessitating transplantation, neurological symptoms, long-term sequelae, and death, highlight the need to determine the pathogenesis of this condition. Hypotheses on the aetiology include adenovirus and SARS-CoV-2 infections and an aberrant immune response to multiple pathogen exposure following lifting of lockdown measures but further investigation is required to reach an informed consensus. METHODS: A literature search was performed on MEDLINE and EMBASE in accordance with PRISMA guidelines for systematic reviews. Primary studies reporting data on severe acute hepatitis of unknown aetiology in children from the COVID-19 era were selected for inclusion in our review. Data on patient demographics, clinical presentation and outcomes, and diagnostic testing for coinfection were extracted. Meta-analysis used a random-effects model. RESULTS: The 33 included studies (30 case series and 3 case-control studies) described a total of 3636 cases of SAHUA (reported 1 January, 2019-31 December, 2022), with a median age of 3.5 years. Of these, 214 children (5.9%) received a liver transplant and 66 (1.8%) died. Whilst data on diagnostic testing was incomplete, the most frequently detected coinfections were with adenovirus and/or adeno-associated virus 2 (AAV2). Other common childhood respiratory and enteric pathogens, such as enterovirus, rhinovirus, and herpesviruses (EBV and HHV-6), were also identified. CONCLUSION: Coinfection with AAV2 and other common childhood pathogens may predispose children to develop this novel severe hepatitis. Altered susceptibility and response to such pathogens may be a consequence of immunological naivety following pandemic restrictions. Further investigations are needed to generate high-quality evidence on aetiology for different patient demographics and geographical areas.


Subject(s)
COVID-19 , Coinfection , Hepatitis , Child , Humans , Child, Preschool , COVID-19/epidemiology , Disease Outbreaks , Pandemics , Acute Disease
2.
J Pharm Sci ; 107(9): 2472-2478, 2018 09.
Article in English | MEDLINE | ID: mdl-29800545

ABSTRACT

Ro 25-6981 is a highly potent and selective blocker of N-methyl-d-aspartate receptors that has been shown to possess both rapid and sustained antidepressant activity. In the present study, we report the biopharmaceutical characterization of Ro 25-6981 by evaluating gastrointestinal stability, transepithelial permeability, stability in human liver microsomes, and in silico metabolic prediction. Moreover, in vivo efficacy of Ro 25-6981 after oral administration was evaluated in animal models of depression. When mixed with 5 different simulated gastrointestinal fluids, no loss of parent compound was observed after 6 h, indicating compound stability in the gastrointestinal environment. At the tested concentrations, Ro 25-6981 was shown to have transepithelial permeability with apparent permeability (Papp) values comparable to highly permeable drugs. Ro 25-6981 was metabolized within 30 min in human liver microsomes, and the metabolic prediction data showed glucuronidation and sulfation as potential metabolic pathways. The in vivo efficacy data suggested that Ro 25-6981, when administered orally at 30 mg/kg, exhibits antidepressant-like activity following oral administration with efficacy comparable to traditional antidepressants that is both dose- and time-dependent. Overall, due to optimal gastrointestinal stability, oral permeability, and oral efficacy, Ro 25-6981 can be a potential therapeutic option for the treatment of depression.


Subject(s)
Antidepressive Agents/administration & dosage , Antidepressive Agents/pharmacokinetics , Microsomes, Liver/drug effects , Phenols/administration & dosage , Phenols/pharmacokinetics , Piperidines/administration & dosage , Piperidines/pharmacokinetics , Administration, Oral , Animals , Caco-2 Cells , Depression/drug therapy , Depression/psychology , Gastric Acid/metabolism , Humans , Immobilization/psychology , Male , Mice , Mice, Inbred C57BL , Microsomes, Liver/metabolism , Treatment Outcome
3.
Mol Cell Probes ; 22(4): 238-43, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18554865

ABSTRACT

We describe the development of a spotted array for the delineation of the most common 14 disease-causing Salmonella serovars in the United States. Our array consists of 414 70 mers targeting core genes of Salmonella enterica, subspecies I specific genes, fimbrial genes, pathogenicity islands, Gifsy elements and other variable genes. Using this array we were able to identify a unique gene presence/absence profile for each of the targeted serovar which was used as the serovar differentiating criteria. Based on this profile, we developed a Matlab programme that compares the profile of an unknown sample to all 14 reference serovar profiles and give out the closest serovar match. Since we have included probes targeting most of the virulence genes and variable genes in Salmonella, in addition to using for serovar detection this array could also be used for studying the virulence gene content and also for evaluating the genetic relation between different isolates of Salmonella.


Subject(s)
Oligonucleotide Array Sequence Analysis/methods , Salmonella enterica/genetics , Cluster Analysis , DNA Probes/classification , DNA Probes/genetics , Substrate Specificity
4.
Infect Immun ; 75(8): 3859-67, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17517862

ABSTRACT

Cj0859c, or FspA, is a small, acidic protein of Campylobacter jejuni that is expressed by a sigma(28) promoter. Analysis of the fspA gene in 41 isolates of C. jejuni revealed two overall variants of the predicted protein, FspA1 and FspA2. Secretion of FspA occurs in broth-grown bacteria and requires a minimum flagellar structure. The addition of recombinant FspA2, but not FspA1, to INT407 cells in vitro resulted in a rapid induction of apoptosis. These data define a novel C. jejuni virulence factor, and the observed heterogeneity among fspA alleles suggests alternate virulence potential among different strains.


Subject(s)
Bacterial Proteins/genetics , Campylobacter jejuni/physiology , Flagella/physiology , Polymorphism, Genetic , Virulence Factors/genetics , Amino Acid Sequence , Apoptosis , Bacterial Proteins/physiology , Campylobacter jejuni/genetics , Campylobacter jejuni/pathogenicity , Cell Line , Cluster Analysis , Flagella/chemistry , Humans , Molecular Sequence Data , Phylogeny , Promoter Regions, Genetic , Virulence Factors/physiology
5.
J Clin Oncol ; 22(4): 671-7, 2004 Feb 15.
Article in English | MEDLINE | ID: mdl-14966090

ABSTRACT

PURPOSE: To describe and assess the current utilization of complementary and alternative medicines (CAMs) in women with a diagnosis of either gynecologic or breast cancer and evaluate their reasons for use. PATIENTS AND METHODS: This study included 250 female patients from the Multidisciplinary Breast Center and 250 patients from the Gynecologic Oncology Center of The University of Texas M.D. Anderson Cancer Center (Houston, TX). Patients were selected by having an odd-numbered medical record number, and they were contacted before their clinic visit. The goals of the study were explained, and verbal consent was obtained. Patients who agreed to participate were asked to bring a written list and the medication bottles of all over-the-counter prescriptions and CAMs with them to clinic. In clinic, the investigator obtained a written informed consent and administered the survey. All patients and surveys were assessable. RESULTS: The most frequently used herbal products and megavitamins/minerals were identified from the patient medication histories. Overall, we found the proportion of patients using CAM to be 48% (95% CI, 44% to 53%; 241 of 500 patients). CAM use was related to patients' educational status: 62% had postgraduate degrees, 50% had college degrees, 56% had some college, and 33% had a high school education or less. Also, among patients using CAMs, only 53.5% had spoken to a healthcare provider regarding CAM therapy. CONCLUSION: The use of CAM is common among women with cancer. Studies need to be conducted to establish if there are any potential drug interactions and/or therapeutic benefit of CAM products. Moreover, there is a need to educate patients and healthcare providers on appropriate and safe use of CAM products.


Subject(s)
Breast Neoplasms/drug therapy , Genital Neoplasms, Female/drug therapy , Phytotherapy , Plant Preparations/therapeutic use , Vitamins/therapeutic use , Adult , Age Distribution , Cohort Studies , Female , Humans , Middle Aged , Multivariate Analysis , Socioeconomic Factors , Texas
SELECTION OF CITATIONS
SEARCH DETAIL
...